Macleods FDA Monday, March 23, 2026 0.00 Neutral

FDA Approves MEXILETINE HYDROCHLORIDE — Macleods Pharmaceuticals Limited

# FDA Approves Generic Mexiletine Hydrochloride from Macleods Pharmaceuticals Macleods Pharmaceuticals Limited has received FDA approval for its generic mexiletine hydrochloride oral formulation (ANDA219987), expanding treatment options for patients with ventricular arrhythmias while intensifying competition in the antiarrhythmic drug market. The approval is expected to increase price competition and improve medication accessibility, potentially benefiting both patients and healthcare payers seeking cost-effective alternatives to branded versions.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day